Slides
Page 1
Corporate Overview: Non-Confidential quoinpharma.com
Page 2
Corporate Overview: Non-Confidential CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements, which are based on our management’s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words. Any statements in this presentation about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: our product pipeline; anticipated regulatory filings; regulatory approvals and the timing thereof; plans for clinical trials and studies and the timing thereof; plans to develop and commercialize products and the highly attractive commercial opportunity. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such risks, uncertainties and other factors relate to, among other things: our ability to generate favorable pre-clinical and clinical trial results; our ability to identify and develop potential product candidates; additional costs or delays associated with unsuccessful clinical trials; the inability to predict the timing of revenue from sales of a future product; the extensive regulatory requirements and future developmental and regulatory challenges we will still face even if we obtain approval for a product candidate; our ability to obtain or maintain orphan drug designation or data exclusivity for our product candidates; our ability to obtain Orphan Disease and Rare Pediatric Disease designations for our product candidates; our manufacturing processes may not be validated and our methodology may not be accepted by the scientific community; and the ability to conduct clinical trials, because of difficulties enrolling patients or other reasons. You should refer to “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on March 13, 2025, as updated by our subsequent filings with the SEC, for a discussion of these and other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate, and you should not place undue reliance on these forward- looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We qualify all of our forward-looking statements by these cautionary statements. This presentation may contain market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this presentation is generally reliable, such information is inherently imprecise. Except as required by law, we assume no obligation to update these forward- looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this presentation, even if new information becomes available in the future. 2
Page 3
Corporate Overview: Non-Confidential - Investment Highlights Experienced Management Team with proven track record of success Focused Rare and Orphan Disease product pipeline Rare Pediatric Designation opportunity for lead products Netherton Syndrome clinical trials underway under open IND in US, EU, Middle East On track for First Netherton Syndrome Treatment Approval in 2026 Establishing own sales infrastructure for US, EU and Japanese market Nine Ex-US and EU Commercial Partnerships in place covering 61 countries Global Netherton Commercial opportunity in Excess of $1 billion 3 Positive Initial Peeling Skin Clinical Data Announced
Page 4
Corporate Overview: Non-Confidential - Product Pipeline 4 Product Candidate Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Approval QRX003 Netherton Syndrome* Peeling Skin Syndrome** SAM Syndrome Palmoplantar Keratoderma*** QRX008 Scleroderma QRX007 Netherton Syndrome *Pivotal Clinical studies underway **Clinical trial initiated ***Clinical testing to commence 2H2025 QRX009 QRX004 Epidermolysis Bullosa Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others
Page 5
Corporate Overview: Non-Confidential - Netherton Syndrome (NS) 5 NS is caused by a mutation of the SPINK5 (serine protease inhibitor, Kazal Type 5) gene SPINK5 mutations LEKTI 1 Kallikreins Antimicrobial Peptides Inflammation InfectionsCorneodesmosomes Barrier Dysfunction Stratum corneum cohesion Lipid processing enzymes IL-1α activated Thinning (loss) of stratum corneum Lamellar bilayers
Page 6
Corporate Overview: Non-Confidential - Netherton Syndrome 6
Page 7
Corporate Overview: Non-Confidential - Netherton Syndrome 7 6000 – 8000 1 in 200,000 • No Approved Treatment or Cure • Patients suffer from multiple severe issues: Infections, allergies, asthma, skin cancer, pruritus, warts Patients in US and Europe Combined. Up to 30,000 in Quoin Partnered Territories Newborns affected • Can be hospitalized on multiple occasions annually • Patients need to coat their whole body with a moisturizer 5-6 times daily
Page 8
Corporate Overview: Non-Confidential - QRX003 Mechanism of Action • Topical lotion to be applied twice-daily to whole body surface • QRX003 performs the function of the missing LEKTI protein • Down regulates the hyperactivity of the KLK5, KLK7 and KLK14 kallikreins to a normalized rate of activity • Restores natural balance of skin shedding and regeneration that is disrupted by the absence of LEKTI in NS patients • Enables skin to fully heal and eliminates key symptoms such as pruritus and severe sleep disturbance • Allows patients to discontinue previously required medications 8
Page 9
Corporate Overview: Non-Confidential - Clinical and Regulatory Pathway • Guidance from FDA • Approximately 20 subjects tested at commercial dose required for approval • Endpoints include: Investigators Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), Pruritus, Patient Satisfaction Scores (PASA) • Pilot Studies: 20% Body Surface Area (BSA) tested • Pivotal Studies: Whole BSA (min 80%) tested 9 Quoin was First Company to File IND for Netherton Syndrome
Page 10
Corporate Overview: Non-Confidential - Pilot Study Data- Open Label Study Part B 10 End Point Baseline 6 weeks 12weeks M-IASI* 18 4 3 WINRS** 7 4 2 IGA*** Moderate Mild Almost Clear PASA Highly positive across all timepoints One Subject: 12 Weeks Twice Daily Dosing, 20% BSA *M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. **WINRS: Worst Itch Numeric Rating Scale, which measures the severity of itch on an 11 -point scale (0 = no itch, 10 = worst imaginable itch). ***IGA: Investigator’s Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the o verall severity of Netherton Syndrome symptoms. Key Findings • Marked improvements observed across all measured clinical endpoints. • No safety concerns identified throughout the study. • Significant improvement in skin appearance from baseline to 12 weeks. • Patient satisfaction scores continued to improve at 12 weeks. • Subject received QRX003. Had been receiving off-label systemic biologic for over 1 year
Page 11
Corporate Overview: Non-Confidential - Twice Daily dosing Images 11 Baseline 12 weeks
Page 12
Corporate Overview: Non-Confidential - 12 Baseline 12 weeks Twice Daily Dosing Images
Page 13
Corporate Overview: Non-Confidential - Pilot Study Data- Open Label Study Part B 13 End Point Baseline 6 weeks 12weeks 16 weeks (4 weeks after discontinuation of treatment) M-IASI* 18 4 3 18 WINRS** 7 4 2 8 IGA*** Moderate Mild Almost Clear Moderate PASA Highly positive across all timepoints Reverted to baseline One Subject: 4 weeks after Discontinuation of Treatment *M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. **WINRS: Worst Itch Numeric Rating Scale, which measures the severity of itch on an 11 -point scale (0 = no itch, 10 = worst imaginable itch). ***IGA: Investigator’s Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the o verall severity of Netherton Syndrome symptoms. Key Findings • Upon discontinuation of treatment, all symptoms reverted to baseline • Supports mechanism of action of QRX003 is a competitive broad spectrum serine protease inhibitor • Emphasizes on-going chronic treatment is essential for continued positive clinical outcome • Subject had continued to be treated with off-label systemic biologic
Page 14
Corporate Overview: Non-Confidential - Pediatric Whole Body Data: 1 subject, 6 weeks 14 End Point* Baseline 6 weeks 6 months IGA 4 (severe) 1 (almost clear) 0-1(clear-almost clear) Pruritus 5 1 0 • Patient discontinued previously required medications including all antihistamines, glucocorticoids and antivirals. • Patient has required no antibiotics since the whole-body application of QRX003 was initiated. • Patient is now experiencing zero nightly sleep disturbances for the first time in her life. • No adverse events have been reported to date. • Study being expanded to 4-6 pediatric subjects
Page 15
Corporate Overview: Non-Confidential - Clinical Program-Pivotal Whole Body Studies 2 Pivotal Studies • Monotherapy • Adjuvant with off-label systemic therapy Same Study Design for both Pivotal Studies • Open Label, baseline control • 12 weeks of treatment BID • Subjects 14 years of age and older • Endpoints: IGA, IASI, Pruritus, PASA: Change from baseline • 12-16 patients per study 15
Page 16
Corporate Overview: Non-Confidential - Commercial Initiatives 16 • NETHERTON NOW’ awareness campaign • Increase awareness within general population, treating physicians, and the patient community • Living with Netherton Video Series Launched • Leveraging social media platforms, participating in derm conferences, working closely with advocacy groups • Pricing: Working with commercial consultants to develop pricing strategy based on actual claims and payer data • Branding: INN/ USAN and brand name development underway • Engaging lobbying firm to interact with local and national lawmakers and establish key relationships
Page 17
Corporate Overview: Non-Confidential - QRX003 For Additional Rare Skin Disorders • Currently no approved treatments for these diseases. • Peeling Skin Study Started in New Zealand. Initial Data Announced • Clinical testing in PPK to commence in 2025. 17 Peeling Skin Syndrome SAM Syndrome Palmoplantar Keratoderma • <1/1000000 • Caused by mutations in the TGM5 gene • Causes peeling of the top layer of skin • Most apparent on the hands and feet Severe dermatitis, multiple allergies, and metabolic wasting (SAM) • Caused by mutations in the desmoglein 1 gene (DSG1) • 4.4 cases per 100,000 • Causes Thickening of the skin on the hands and feet • Can be acquired or inherited
Page 18
Corporate Overview: Non-Confidential First Subject Peeling Skin Data End Point Baseline 12 weeks M-IASI* 36 12 IGA** 4 (Severe) 2 (Mild) CDQLI*** 19 11 18 *M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. **IGA: Investigator’s Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of disease symptoms. ***The CDQLI is a validated clinical tool designed for children aged 4-15 that is used to measure the impact of their skin disease on a child’s quality of life in terms of symptoms, leisure activities, sleep, school, personal relationship and treatment. The scale for the CDQLI is 0-30.
Page 19
Corporate Overview: Non-Confidential - Strong Management Team with Proven Track Record of Success 19 Dr. Michael Myers Denise Carter Gordon Dunn CEO COO CFO Name Position Experience Seasoned executives with over 90 years experience developing products based on drug delivery technologies Proven track record transitioning companies to key inflection points, including mergers, reverse mergers acquisitions and IPOs Raised over $250M in private and public markets. Deep commercialization experience in US and Europe
Page 20
THANK YOU quoinpharma.com
Page 21
Corporate Overview: Non-Confidential - Appendices 21
Page 22
Corporate Overview: Non-Confidential - QRX003 Clinical Programs- Pilot Two Pilot Studies 1. Placebo Controlled* no off-label systemic therapy 2. Open Label, with off-label systemic therapy • Part A: Once daily dosing Part B: Twice daily dosing • Both studies: 12 weeks dosing, test materials applied to 20% BSA • 19 subjects recruited in total 22 Transitioned to ‘Whole Body’ Pivotal Studies *Database still locked. No efficacy data available yet.
Page 23
Corporate Overview: Non-Confidential - Pilot Study Data- Open Label Study Part A Six Subjects: 12 Weeks Once Daily Dosing, 20% BSA Pruritus 23 *All data reported is change from baseline in Open Label single arm study. All subjects received QRX003. All had been treated with off-label systemic biologics for over 1 year PASA IGA/M-IASI • 5 subjects reported absence of or negligible pruritis • 1 subject unchanged • 3 subjects demonstrated improvement on completion • 3 subjects showed improvement during study • Positive feedback across a number of metrics including: ease of use, time to start working, overall satisfaction, lack of side effects